Halozyme Interim CFO files initial ownership

HALOZYME THERAPEUTICS, INC. filed an initial ownership report for Interim CFO David A. Ramsay.

Accepted by SEC EDGAR 03/23/2026 - 06:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. filed an initial ownership report for Interim CFO David A. Ramsay. This Form 3 shows his status as an officer but does not list any equity transactions or holdings in the provided data. It is an administrative disclosure of insider status rather than a trading event.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the HALO Form 3 filing for Interim CFO David A. Ramsay show?

The Form 3 filing identifies David A. Ramsay as Interim CFO of HALOZYME THERAPEUTICS, INC. It is an initial insider ownership report and, in the provided data, does not list any equity transactions or holdings.

Does the HALO Form 3 for David A. Ramsay report any stock purchases or sales?

No transactions are reported in the provided Form 3 data. The transaction summary shows zero buys, zero sells, and zero derivative exercises, indicating no reportable trading activity in this filing excerpt.

What insider role is disclosed in HALOZYME THERAPEUTICS Form 3?

The filing discloses that David A. Ramsay serves as an officer of HALOZYME THERAPEUTICS, INC. with the title of Interim CFO. This establishes him as a reporting person subject to insider ownership and transaction reporting rules.

Why is a Form 3 important for HALOZYME (HALO) investors?

Form 3 marks the point when an individual becomes an insider at HALOZYME THERAPEUTICS, INC. It helps investors track which executives and major holders are subject to ongoing reporting of their equity ownership and future transactions.

Does the HALO Form 3 include any derivative securities for David A. Ramsay?

The derivative summary in the provided data is empty. This means no stock options, warrants, or other derivative securities are listed for David A. Ramsay in this particular Form 3 excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

RAMSAY DAVID A

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ James R. Oehler, Attorney-in-Fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)